- 3'UTRs and miRNAs
- Empty Vector Suite
- Lightswitch Assay Reagents
- Transfection Reagents
SwitchGear Genomics Launches the Largest Collection of Transcription Factor Response Element Reporter Vectors
November 29th, 2011
SwitchGear offers 91 Response Element Reporters for well-studied pathways to LightSwitch product line in addition to collection of 18,000 endogenous human promoter GoClone reporters.
Menlo Park, CA (PRWEB) November 29, 2011
SwitchGear Genomics' LightSwitch Luciferase Assay System identifies functional sequence variants associated with disease
June 1st, 2011 Recent publication highlights that LightSwitch Luciferase Assay System enables researchers to measure the function of hundreds of sequence variants in 3′UTRs and promoters MENLO PARK, CA.
June 1st, 2011 SwitchGear agreement with Cosmo Bio will allow broader exposure in Japan
SwitchGear Genomics announces distribution agreement for FuGENE® HD transfection reagent and novel transfection optimization kit
January 19th, 2011 SwitchGear is pleased to offer for direct sale FuGENE HD transfection reagent along with proprietary transfection optimization kit MENLO PARK, Calif. – January 19, 2011 – SwitchGear Genomics Inc., a leading provider of products for studying the regulatory elements in the human genome, today announced that the company will offer FuGENE® HD transfection reagent as an individual product and as part of its novel LightSwitch Transfection Optimization Kit.
SwitchGear Genomics introduces innovative LightSwitch Luciferase Assay System™ for screening gene regulation in living cells
January 12th, 2011 Comprehensive solution for reporter assays includes a genome-wide collection of cloned human promoters and 3’UTRs in a novel luciferase vector that that utilizes an optimized luciferase reagent MENLO PARK, Calif. – January 12, 2011 – SwitchGear Genomics Inc., a leading provider of products for studying the regulatory elements in the human genome, today announced the launch of the innovative LightSwitch Luciferase Assay System™, a comprehensive reporter assay solution for measuring transcriptional activation and translational efficiency in living cells.
Sigma® Life Science and SwitchGear Genomics to Co-develop Simplified Novel microRNA Target Validation System
August 10th, 2010 FORWARD INQUIRIES TO: Sigma-Aldrich Sarah Bruno + (1) 314-286-7810 firstname.lastname@example.org MEDIA INQUIRIES: kdm communications limited Sarah Khan +44 (0) 1234 210555 email@example.com St. Louis, MO. – August 9, 2010 – Sigma Life Science, the innovative biological products and services research business of Sigma-Aldrich® (Nasdaq:SIAL), and SwitchGear Genomics, Inc. today announced a joint project to develop and distribute a novel microRNA (miRNA) target reporter system.
April 1st, 2010 Collections of experimentally-validated human 3’UTR reporter vectors empower researchers to screen for miRNA function in cells MENLO PARK, Calif. – April 1, 2010 – SwitchGear Genomics, Inc., a leading provider of products for studying regulatory elements in the human genome, today announced the launch of a unique research tool for screening for miRNA function in living cells.
Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity
November 18th, 2009 Madison, WI (November, 18, 2009) — Promega Corporation and SwitchGear Genomics announce a novel method for characterizing DNA-protein interactions. Results of a study using the HaloCHIP™ System and high-throughput promoter assays demonstrate the ability to correlate DNA binding events to transcriptional activation or repression for the CREB transcription factor.
SwitchGear Genomics launches novel high-throughput screening products for profiling biological pathway regulation
October 14th, 2009 Collections of experimentally-validated human promoter reporter vectors empower researchers to measure transcriptional regulation across genes in a variety of different biological pathways MENLO PARK, Calif. – October 14, 2009 – SwitchGear Genomics, Inc., a leading provider of products for studying regulatory elements in the human genome, today announced the availability of the first cost-effective, high-throughput research tools for screening transcriptional activation and repression in a number of key biological pathways.